Biogen Inc. (NASDAQ:BIIB) was among Jim Cramer’s stock calls on Mad Money recently. Toward the end of the lightning round, a caller asked what Cramer thinks of the stock, and he commented:
Well, I read the upgrade today by Wells Fargo, and it talked about a bunch of revenue streams. including Alzheimer’s, and it was very impressive. I actually said, you know what? I got to reopen the file on Biogen. It looks pretty… good. I also like Gilead, for that matter.
Photo by Anna Nekrashevich on Pexels
Biogen Inc. (NASDAQ:BIIB) develops therapies for serious neurological and autoimmune conditions, including multiple sclerosis, Alzheimer’s disease, and spinal muscular atrophy. Patient Capital Management stated the following regarding Biogen Inc. (NASDAQ:BIIB) in its fourth quarter 2025 investor letter:
This quarter we entered three new positions and exited one position. We increased our exposure to Biogen Inc. (NASDAQ:BIIB) in the quarter by buying long-dated call options expiring in 2028 with a strike price of $150. We continue to think Biogen is an attractive asset over the long term. The company has a number of late-stage pipeline assets that should reach the market over the next few years, at the same time that its Alzheimer’s franchise should continue to ramp as blood-based biomarkers and subcutaneous injections broaden the potential treatable universe. Longer term, we believe Biogen is positioning itself to own multiple stages of the Alzheimer’s disease lifecycle, similar to its historical approach in multiple sclerosis. With a cleaned-up cost structure, a more focused research effort, and a growing late-stage pipeline, we continue to view the risk/reward as attractive.
While we acknowledge the potential of BIIB as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.
READ NEXT: 33 Stocks That Should Double in 3 Years and 15 Stocks That Will Make You Rich in 10 Years
Disclosure: None. Follow Insider Monkey on Google News.
